A small retrospective study of women receiving taxane therapy for breast or ovarian cancer while pregnancy showed no statistically significant outcomes in maternal or fetal health.
Read the abstract here
Related Topics
Global Ovarian Cancer Research Consortium Awards Inaugural AI Accelerator Grant with Microsoft’s AI for Good Lab
$1 million global research award, plus an additional $1 million in compute support, advances AI-driven efforts to personalize ovarian cancer care The Global Ovarian Cancer Research Consortium today awarded its inaugural AI Accelerator Grant to an international team of researchers to examine whether artificial intelligence (AI) can improve how survival and treatment response are predicted … Continued
FDA Approves First Ovarian Cancer Immunotherapy for PD-L1–Positive Platinum-Resistant Disease
The U.S. Food and Drug Administration (FDA) has approved the first immunotherapy regimen shown to extend survival in a subset of ovarian cancer patients. The FDA authorized Keytruda (pembrolizumab), made by Merck, in combination with chemotherapy, for PD-L1–positive, platinum-resistant epithelial ovarian, fallopian tube, and primary peritoneal cancers. Keytruda plus weekly Taxol (paclitaxel), with or without … Continued
OCRA-Funded Study Provides Clear New Evidence That Opportunistic Salpingectomy Drastically Reduces Risk of Ovarian Cancer
A new study published February 2 in JAMA Network Open provides the clearest evidence to date that opportunistic salpingectomy—the removal of the fallopian tubes during another gynecologic surgery—can dramatically reduce the risk of ovarian cancer. Led by a B.C.-based international collaboration known as the Ovarian Cancer Observatory, the study found that people who underwent opportunistic … Continued